Developing a new drug for human use is a lengthy and costly process that takes an average of 10 years or more and costs approximately $2.6 billion. Yet, the return on investment can be astounding when one considers the number of people a successful drug can help.
Before a drug goes to market, its efficacy, safety, and mechanism of action (MOA) must be thoroughly understood. In vivo models work to minimize adverse side effects and maximize therapeutic properties of a drug before it is taken to clinical trials. Biocytogen is a one-stop CRO that provides humanized mouse models for immuno-oncology and autoimmune/inflammatory disease targets, which can help move projects from target to IND application.
In vivo Models for Research
Although scientists have made significant technological advancements for in vitro models and methods, those applications are limited when it comes to human translational research. Moreover, ethical and safety concerns require that drugs be proven safe with certain levels of efficacy before they are approved for medical use. To profile drugs, toxicology and efficacy studies are primarily performed in animal models for research. As such, in vivo models are indispensable in preclinical profiling, especially in cancer research and drug development.
Anatomically and physiologically speaking, humans and animals are very similar as they share the same organs and organ systems that perform similar life functions. Particularly, rodents such as mice and rats are practical as in vivo models. Although non-human primates are still primarily used for IND-enabling studies, supply shortages have led to the alternative use of genetically modified rodents. Discover our animal models for research below.
Biocytogen provides a number of genetically-modified in vivo models for basic and preclinical research, which includes syngeneic mouse models and xenografts. Syngeneic mouse tumor models are defined as mice inoculated with tumor cells that are from the same genetic background. Syngeneic mouse models have an intact immune system, allowing them to be used for efficacy assessment and screening tools for immunotherapies. Our humanized immune checkpoint mouse models, engineered to express human forms of immune signaling molecules, are ideal for studying anti-human antibody activity. We also offer other humanized models expressing common tumor cell-associated antigens (TAA).
To date, many pharmaceutical companies have received Investigational New Drug (IND) approval with the help of BioMice’s target humanized mice for RDT and DART studies. As a leader in the field of humanized model generation, we have ownership of intellectual property for our in vivo models, under which use of these models by our clients is protected.
In contrast to syngeneic models, xenograft models use cells from one species to transplant into another, often human cells into an immunodeficient mouse. Depending on whether the cells come from a patient or an established cell line, patient-derived xenografts (PDX) and cell-derived xenografts (CDX) can allow in vivo testing of anti-cancer treatments on human tumors. Through adoptive transfer of human-derived cells or tissue into the highly immune-deficient B-NDG™ mouse, human immune systems can be reconstituted and studied in vivo.
Gene Editing Capabilities for in vivo model generation
Based on gene editing services, Biocytogen has grown into a global leader of in vivo model generation. Our following capabilities enabled our comprehensive collection of animal models for research and drug efficacy evaluation.
- Gene editing via homologous recombination
- CRISPR/Cas9
- SUPCE
Cell Line Engineering Services
Cell line engineering — also referred to as cell line editing — involves the genetic altering of cell lines to determine the effects of a specific alteration. In studying phenotypic changes of these cells, scientists can drive the discovery of new drugs and therapies for various types of cancer cells. Biocytogen has more than a decade of experience engineering a wide range of cell lines, ranging from HeLa, 293FT and HEK 293 to more challenging-to-confect cell lines such as fibroblasts, endothelium-derived, neuroblastoma-derived, bone-marrow-derived, hepatocellular-carcinoma-derived cells, and hiPSC.
Biocytogen — A World Leader in Animal & Cell Line Engineering Services
Biocytogen has been serving customers around the world, both in academia and industry, for over a decade. With our commitment to quality in everything we do, we’ll work closely with you to deliver models and services that meet your precise specifications in a timely manner. We offer world-leading, cutting-edge technology platforms, superior service, a fast timeline, a large collection of animal models for research and a 100 percent satisfaction guarantee.
Haimen (Jiangsu) Animal Center
We have established a world-class animal model production center, including three animal faculties encompassing a total of approximately 55,500 sq. m., with annual supply capacity of 800,000 gene edited mice. Shipping is available to our customers worldwide. Check our animal models below:
- Humanized Immune-Checkpoint Mice
- Humanized Cytokines Mice
- Humanized GPCR Mice
- Immunodeficient (B-NDG) Mice
- Cre Mouse/Rat Models
- Other Genetically Modified Mouse/Rat Models
- Humanized Tumor Cell Lines
FAQ
Related Services and Studies
For more information about our products and services, contact us today.
